Advert - Sanofi - SANOFI – CASE/0688/08/25

For a press release which promoted Sanofi’s medicine (Beyfortus (nirsevimab)) to the public, included a claim that was not capable of substantiation, and included a misleading comparison with another pharmaceutical company’s vaccine (thereby disparaging it), Sanofi was ruled in breach of the following clauses of the 2024 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 5.1 - Failing to maintain high standards

Clause 6.1 - Making a misleading comparison

Clause 6.2 - Making a claim that was incapable of substantiation

Clause 6.6 - Disparaging another company’s medicine

Clause 26.1 - Advertising a prescription only medicine to the public

Clause 26.2 - Providing inaccurate and unbalanced information to the public